Joenja
The first and only therapy that is designed to correct the underlying immune defect in APDS1-4
APDS, activated PI3Kδ syndrome.
About Joenja
Joenja is the first and only FDA-approved
therapy indicated for the treatment
of APDS. Joenja helps address both immune
deficiency AND immune dysregulation.5
Clinical Data
Joenja demonstrated significant efficacy
and safety tolerability in a Phase 3,
randomized controlled clinical trial.1
Access & Patient Support
Obtain information regarding access to
Joenja, the APDS Assist program, and other
helpful resources for your patients with
APDS.
About APDS
APDS is a rare, primary immunodeficiency.
Hyperactivity along the PI3Kδ signaling
pathway disrupts immune cell balance,
causing immune deficiency and
immune dysregulation.1,2,5,6
Valuable Updates
Your resource for clinical developments and important information regarding APDS and Joenja.
Not actual patients.
Help your patients with APDS remember every dose with the free Joenja reminder tone.
activated phosphoinositide 3-kinase δ syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry. Front Immunol. 2018;9:543. doi:10.3389/
fimmu.2018.00543 3. Rao VK, Webster S, Dalm VASH, et al. Effective “activated PI3Kδ syndrome”—targeted therapy with the PI3Kδ inhibitor leniolisib. Blood. 2017;130(21):2307-2316. doi:10.1182/
blood-2017-08-801191 4. Data on file. Pharming Healthcare, Inc. 5. Rao VK, Webster S, Šedivá A, et al. A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ
syndrome. Blood. 2023;141(9):971-983. doi:10.1182/blood.2022018546 6. Angulo I, Vadas O, Garçon F, et al. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway
damage. Science. 2013;342(6160):866-871. doi:10.1126/science.1243292
